Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis

2005 ◽  
Vol 16 (3) ◽  
pp. 209-216 ◽  
Author(s):  
Christina Keen ◽  
Sofi Johansson ◽  
Jesper Reinholdt ◽  
Mikael Benson ◽  
Goran Wennergren
Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2339 ◽  
Author(s):  
Faiza Mahmood ◽  
Geir Hetland ◽  
Ivo Nentwich ◽  
Mohammad Reza Mirlashari ◽  
Reza Ghiasvand ◽  
...  

Since Agaricus blazei Murill (AbM) extract reduced specific IgE and ameliorated a skewed Th1/Th2 balance in a mouse allergy model, it was tested in blood donors with self-reported, IgE-positive, birch pollen allergy and/or asthma. Sixty recruited donors were randomized in a placebo-controlled, double-blinded study with pre-seasonal, 7-week, oral supplementation with the AbM-based extract AndosanTM. Before and after the pollen season, questionnaires were answered for allergic rhino-conjunctivitis, asthma, and medication; serum IgE was measured, and Bet v 1-induced basophil activation was determined by CD63 expression. The reported general allergy and asthma symptoms and medication were significantly reduced in the AbM compared to the placebo group during pollen season. During the season, there was significant reduction in specific IgE anti-Bet v 1 and anti-t3 (birch pollen extract) levels in the AbM compared with the placebo group. While the maximal allergen concentrations needed for eliciting basophil activation before the season, changed significantly in the placebo group to lower concentrations (i.e., enhanced sensitization) after the season, these concentrations remained similar in the AndosanTM AbM extract group. Hence, the prophylactic effect of oral supplementation before the season with the AbM-based AndosanTM extract on aeroallergen-induced allergy was associated with reduced specific IgE levels during the season and basophils becoming less sensitive to allergen activation.


2020 ◽  
Vol 181 (11) ◽  
pp. 831-838
Author(s):  
Andrzej Bozek ◽  
Jolanta Zalejska Fiolka ◽  
Anna Krajewska Wojtys ◽  
Beata Galuszka ◽  
Anna Cudak

<b><i>Introduction:</i></b> Different endotypes of rhinitis are known, but its pathomechanism has not been conclusively established. For example, the precise difference between systemic allergic rhinitis (SAR) and local allergic rhinitis (LAR) is still being checked. Comparison of patients with LAR and with allergies to birch of those with intermittent allergic rhinitis, same allergy, or with non-allergic rhinitis (NAR) was the purpose of this study. <b><i>Methods:</i></b> Twenty-six patients with LAR, 18 with SAR and allergy to birch, and 21 with NAR were included. Patients who met the inclusion criteria were selected to undergo the following procedures at baseline: medical examinations, nasal provocation test (NPT), detection of nasal-specific IgE to birch as well as basophil activation test (BAT). All immunological parameters were detected before and after NPT. <b><i>Results:</i></b> Concentration of nasal IgE to Bet v1 increased comparably in the LAR and SAR groups after NPT to birch as follows: in 21 (81%) patients with LAR, 14 (78%) with SAR, and in everyone in the NAR group. Serum concentration of allergen-specific IgE to Bet v1 increased significantly from a median of 20.7 (25–75% interval: 11.2–35.6) IU/mL to 29.9 (13.6–44.1) (<i>p</i> = 0.028) after NPT in patients with SAR. Allergen-specific IgE to Bet v1 was absent in all patients with LAR and NAR before and after NPT. BAT with Bet v1 was positive in 22 (85%) patients with LAR, in 14 (78%) with SAR, and 2 (9.5%) with NAR. <b><i>Conclusion:</i></b> These obtained data suggest there are no potential mechanisms that could explain LAR compared to SAR.


2009 ◽  
Vol 15 (26) ◽  
pp. 3261 ◽  
Author(s):  
Arthur C Ouwehand ◽  
Merja Nermes ◽  
Maria Carmen Collado ◽  
Nina Rautonen ◽  
Seppo Salminen ◽  
...  

2020 ◽  
Author(s):  
Premkumar Siddhuraj ◽  
Franziska U Nordström ◽  
Prajakta Jogdand ◽  
Gayathri Elongovan ◽  
Michiko Mori ◽  
...  

Abstract Background : Allergic rhinitis (AR) is one of the most common medical conditions in the westernized world. Recent data suggest AR to be far more immunologically complex than the archetypical allergic Th2-driven eosinophilic inflammation and new methodological approaches are needed to decode this complexity. Methods : This study explores a novel histology-based analysis of circulating leukocytes for detailed profiling of immune cells using routine clinical blood samples. In brief, leukocytes were purified with minimal ex-vivo artefacts, embedded into agarose-paraffin pellets and sectioned for cutting-edge immunohistochemistry-based immune cell profiling. Blood leukocyte mapping was performed in 16 patients with seasonal AR outside and during the birch pollen season. Results : Our methodological feasibility test confirmed that the > 5000 cross sectioned leukocytes typically present in a pellet section had well preserved morphology and cell marker epitopes, allowing for robust quantitative analysis of immune-stained slides. Blood leukocyte samples collected during the allergen season had statistically higher levels of markers for eosinophils, neutrophils, monocytes and CD8 lymphocytes compared to the off-season baseline. No change was observed for CD20 B-lymphocytes, total CD3 T cells and basophils. Subclassification of CD4+ T-helper cells demonstrated a parallel and significant expansion of Th2 and Th17 cells during the pollen season, while Th1 cells remained unchanged. Whereas absolute basophils numbers were unaltered, a significant increase of the basophil markers GATA2 and CPA3 was observed during the pollen season. Conclusions: Apart from representing a positive method feasibility validation, our study provides further evidence of complex and parallel Th2 and Th17 immune signatures in seasonal AR. Our data also forward GATA2 and basophil CPA3 as potential biomarkers for ongoing allergic inflammation. It is thus proposed that the present histology-based approach, with its broad applicability, represents a powerful tool for decoding systemic immune alterations and guide novel biomarker strategies for improved personalized medication.


Allergy ◽  
2018 ◽  
Vol 73 (9) ◽  
pp. 1851-1859 ◽  
Author(s):  
K. Karatzas ◽  
N. Katsifarakis ◽  
M. Riga ◽  
B. Werchan ◽  
M. Werchan ◽  
...  

Allergy ◽  
2020 ◽  
Vol 75 (5) ◽  
pp. 1099-1106 ◽  
Author(s):  
Oliver Pfaar ◽  
Kostas Karatzas ◽  
Katharina Bastl ◽  
Uwe Berger ◽  
Jeroen Buters ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document